Michael Weller

Research interests

Publications

• Glioma progression is shaped by genetic evolution and microenvironment interactions

  Cell · 2022 · https://doi.org/10.1016/j.cell.2022.04.038

• Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

  Neuro-Oncology · 2020 · https://doi.org/10.1093/neuonc/noaa106

• Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

  JAMA Oncology · 2020 · 10.1001/jamaoncol.2020.1024

• EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

  Nature Reviews Clinical Oncology · 2020 · https://doi.org/10.1038/s41571-020-00447-z

• Molecular targeted therapy of glioblastoma

  Cancer Treatment Reviews · 2019 · 10.1016/j.ctrv.2019.101896

• Longitudinal molecular trajectories of diffuse glioma in adults

  Nature · 2019 · 10.1038/s41586-019-1775-1

• cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”

  Acta Neuropathologica · 2018 · 10.1007/s00401-018-1913-0

• Current state of immunotherapy for glioblastoma

  Nature Reviews Clinical Oncology · 2018 · 10.1038/s41571-018-0003-5

• EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours

  Annals of Oncology · 2017 · 10.1093/annonc/mdx221

• Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

  JAMA · 2017 · https://doi.org/10.1001/jama.2017.18718

• Lomustine and Bevacizumab in Progressive Glioblastoma

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1707358

• DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30155-9

• European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30194-8

• Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30517-x

• Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30517-x

• Advances in the molecular genetics of gliomas — implications for classification and therapy

  Nature Reviews Clinical Oncology · 2016 · 10.1038/nrclinonc.2016.204

• Glioma

  Nature Reviews Disease Primers · 2015 · 10.1038/nrdp.2015.17

• Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials

  Neuro-Oncology · 2015 · 10.1093/neuonc/nov095

• Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)00088-1

• MGMT testing—the challenges for biomarker-based glioma treatment

  Nature Reviews Neurology · 2014 · 10.1038/nrneurol.2014.100

• Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)70379-1

• EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)70011-7

• Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

  The Lancet Oncology · 2012 · 10.1016/s1470-2045(12)70164-x

• Standards of care for treatment of recurrent glioblastoma—are we there yet?

  Neuro-Oncology · 2012 · 10.1093/neuonc/nos273

• An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

  Nature · 2011 · 10.1038/nature10491

• Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

  Acta Neuropathologica · 2010 · 10.1007/s00401-010-0781-z

• Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2009.23.0805

• NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2009.23.6497

• MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

  Nature Reviews Neurology · 2009 · 10.1038/nrneurol.2009.197

• Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

  The Lancet Oncology · 2009 · https://doi.org/10.1016/s1470-2045(09)70025-7

• Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

  Acta Neuropathologica · 2009 · 10.1007/s00401-009-0561-9

• Correlation of O 6 -Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2007.11.5964

• Long-term survival with glioblastoma multiforme

  Brain · 2007 · 10.1093/brain/awm204

• Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma

  New England Journal of Medicine · 2005 · https://doi.org/10.1056/nejmoa043330

• MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma

  New England Journal of Medicine · 2005 · https://doi.org/10.1056/nejmoa043331

• Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo

  Nature Medicine · 2002 · 10.1038/nm735

Current projects

No projects listed.